Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis
Authors' conclusion
These real-world data emphasize a marked shift in T2DM treatment towards novel substance classes. However, the use of incretin mimetics remained low. Significantly more patients reached HbA1c targets in the most recent cohort.
Study context
- Population
- Patients undergoing elective coronary angiography at a tertiary care hospital in Europe (high CV risk)
- Participants
- 2,158 patients3 sequential studies
- Exposure
- Glucose-lowering therapy across three study periods
- OS1n = 672
- OS2n = 1,005
- OS3n = 481
- Outcome
- Glucose-lowering therapy patterns
Methodological detailsthree sequential cohorts, single-centre, tertiary care hospital, real-world
- Three sequential cohorts
- Single-centre
- Tertiary care hospital
- Real-world
Main finding
As reported in the abstract
Glucose-lowering therapy patterns
Metformin (% of reported glucose-lowering drugs) OS1 33.9% · OS2 41.8% · OS3 32.0%
SGLT2i (% of reported glucose-lowering drugs; most frequent class) OS3 34.0%
Max drugs in combination in a single patient OS3 5
Observational data: associations, not effects.
Further findings
HbA1c <7% — OS1 vs OS3 · trend across OS1, OS2, OS3
P for trend < 0.001
T2DM newly diagnosed at admission (no diabetes medication) — OS1 vs OS3 · trend across OS1, OS2, OS3
P for trend < 0.001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →